RT Journal Article
T1 Brain Organoids to Evaluate Cellular Therapies.
A1 Garcia-Delgado, Ana Belen
A1 Campos-Cuerva, Rafael
A1 Rosell-Valle, Cristina
A1 Martin-Lopez, Maria
A1 Casado, Carlos
A1 Ferrari, Daniela
A1 Marquez-Rivas, Javier
A1 Sanchez-Pernaute, Rosario
A1 Fernandez-Muñoz, Beatriz
K1 3 Rs
K1 brain organoids
K1 cell therapy
K1 neural progenitors
K1 neural stem cells
K1 reduction
K1 translation
K1 Unidad de Producción y Reprogramación Celular (UPRC)
K1 Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RAdytTA)
AB Animal models currently used to test the efficacy and safety of cell therapies, mainly murine models, have limitations as molecular, cellular, and physiological mechanisms are often inherently different between species, especially in the brain. Therefore, for clinical translation of cell-based medicinal products, the development of alternative models based on human neural cells may be crucial. We have developed an in vitro model of transplantation into human brain organoids to study the potential of neural stem cells as cell therapeutics and compared these data with standard xenograft studies in the brain of immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Neural stem cells showed similar differentiation and proliferation potentials in both human brain organoids and mouse brains. Our results suggest that brain organoids can be informative in the evaluation of cell therapies, helping to reduce the number of animals used for regulatory studies.
PB MDPI AG
SN 2076-2615
YR 2022
FD 2022-11-15
LK http://hdl.handle.net/10668/20758
UL http://hdl.handle.net/10668/20758
LA en
NO García-Delgado AB, Campos-Cuerva R, Rosell-Valle C, Martin-López M, Casado C, Ferrari D, et al. Brain Organoids to Evaluate Cellular Therapies. Animals (Basel). 2022 Nov 15;12(22):3150.
DS RISalud
RD Apr 7, 2025